Results 1 to 10 of about 12,571 (195)
Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review [PDF]
Expert Opinion on Drug Metabolism and Toxicology, 2021 Introduction: Idiosyncratic drug-induced liver injury (DILI) is an unpredictable event, and there are no specific biomarkers that can distinguish DILI from alternative explanations or predict its clinical outcomes. Areas covered: This systematic review summarizes the available evidence for all biomarkers proposed to have a role in the diagnosis or ...
Edmond Atallah +2 more
exaly +10 more sources
Clinical management of patients with drug‐induced liver injury (DILI) [PDF]
United European Gastroenterology Journal, 2021 AbstractDrug‐induced liver injury (DILI) should be considered in all patients with recent elevation of liver tests without obvious etiology and normal hepatobiliary imaging. There is currently no biomarker that is helpful in diagnosis which relies on clinical and laboratory findings.
Einar S Björnsson
exaly +5 more sources
Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes [PDF]
Archives of Toxicology, 2021 AbstractDrug-induced liver injury (DILI) is an adverse toxic hepatic clinical reaction associated to the administration of a drug that can occur both at early clinical stages of drug development, as well after normal clinical usage of approved drugs. Because of its unpredictability and clinical relevance, it is of medical concern. Three DILI phenotypes
Guillermo Quintás +2 more
exaly +8 more sources
Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives [PDF]
Current Drug Metabolism, 2018 Drug-induced Liver Injury (DILI) is an important cause of acute liver failure cases in the United States, and remains a common cause of withdrawal of drugs in both preclinical and clinical phases.A structured search of bibliographic databases - Web of Science Core Collection, Scopus and Medline for peer-reviewed articles on models of DILI was performed.
Lucija Kuna +2 more
exaly +5 more sources
Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI) [PDF]
Molecular Pharmaceutics, 2020 Drug-induced liver injury (DILI) is one the most unpredictable adverse reactions to xenobiotics in humans and the leading cause of postmarketing withdrawals of approved drugs. To date, these drugs have been collated by the FDA to form the DILIRank database, which classifies DILI severity and potential.
Daniel H Foil +2 more
exaly +5 more sources
When Is Suspected Drug-Induced Liver Injury (DILI) Not DILI? An Analysis of Unlikely Cases From the Drug-Induced Liver Injury Network. [PDF]
Am J Gastroenterol, 2023 INTRODUCTION: Diagnosis of drug-induced liver injury (DILI) is difficult. We reviewed cases in the DILI Network prospective study that were adjudicated to have liver injury due to other causes to discover pearls for improved diagnostic accuracy.
Barritt AS +6 more
europepmc +3 more sources
The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment. [PDF]
Metabolites, 2022 Drug-induced liver injury (DILI) is one of the most frequent adverse clinical reactions and a relevant cause of morbidity and mortality. Hepatotoxicity is among the major reasons for drug withdrawal during post-market and late development stages, representing a major concern to the pharmaceutical industry.
Moreno-Torres M, Quintás G, Castell JV.
europepmc +6 more sources
Drug-induced liver injury (DILI) - mechanisms and diagnostic [PDF]
Farmacja Polska, 2022 The drug-induced liver injury (DILI) is one of the leading causes of the liver disease in developed countries. These injuries may be the result of constant drug hepatotoxicity or idiosyncrasy associated with the drug or its metabolite.
Marta Małysz +3 more
doaj +2 more sources
Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)-In Vitro Testing. [PDF]
Pharmaceutics, 2022 Bile acids and bile salts (BA/BS) are substrates of both influx and efflux transporters on hepatocytes. Canalicular efflux transporters, such as BSEP and MRP2, are crucial for the removal of BA/BS to the bile. Basolateral influx transporters, such as NTCP, OATP1B1/1B3, and OSTα/β, cooperate with canalicular transporters in the transcellular vectorial ...
Tátrai P, Erdő F, Krajcsi P.
europepmc +4 more sources
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. [PDF]
Drug Saf, 2021 Causality assessment for suspected drug-induced liver injury (DILI) during drug development and following approval is challenging. The IQ DILI Causality Working Group (CWG), in collaboration with academic and regulatory subject matter experts (SMEs), developed this manuscript with the following objectives: (1) understand and describe current practices;
Hey-Hadavi J +16 more
europepmc +5 more sources